Blog
ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia
21
Jul
Jul
ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs generally known as Rycals®, announced today the enrollment of the primary patient in a Phase 2 proof of concept clinical trial using its Rycal ARM210 (also generally known as S48168), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia […]